The BA.2 variant is responsible for 60 to 80 percent of Israel's new COVID cases, although no solid information shows a fourth dose offers greater protection against infection and serious illness
Health Ministry updates earlier caseload count, indicating positivity rate of tests higher than previously reported; panel of experts says they hope Health Ministry adopts their recommendation for 4th booster for older and vulnerable population
Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Follow
Dec. 17, 2020
Israelis participating in clinical trials of a locally produced potential vaccine against the coronavirus can still get the vaccine made by Pfizer, health authorities clarified on Sunday.
Clinical trials of any drug or vaccine involve controls: one group receives the actual active ingredient and another group gets a placebo, which has no biological effect. Under normal conditions, neither the tester nor the testee know in advance whether a subject received a real drug or placebo.
Now however due to the circumstances, if a test subject wishes to receive the Pfizer inoculation, their file will be opened; if they received a placebo and not the Israeli vaccine, they will be informed accordingly. Placebo recipients can then get the Pfizer shot, explains Dr. Erez Birnbaum, CEO of the Assuta Ashdod Medical Center, which is one of the sites at which the Israeli vaccine is being tested.